Andromeda Biotech Acquires DiaPep277 Rights From Teva Pharmaceutical Industries Limited
Published: Feb 24, 2014
YAVNE, Israel, Feb. 24, 2014 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. announces that it entered into an agreement with Teva Pharmaceutical Industries Ltd. for the acquisition of Teva's rights for Andromeda's drug, DiaPep277®, for the treatment of Type 1 Diabetes.
Help employers find you! Check out all the jobs and post your resume.